Description
Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments
The global market for human vaccines experienced strong growth through 2013 with the introduction of new vaccines. These new products and other trends are well-covered in Vaccines: The World Market. The Kalorama information report examines the global market for vaccines, covering specifically commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable.
Vaccination protects not only individuals, but also entire communities from diseases spread by person-to-person transmission. The high growth rates and successful launch of several recent products have kept interest in the global vaccine market high. This report investigates the changes vaccine manufacturers have undergone in the past year, providing world market analysis, identifying the key players, and outlining critical trends in this fast-changing industry.
Included in this report are current market size and forecasts to 2020 for the following vaccines:
Pediatric Vaccines:
- Pneumococcal
- Combinations
- Varicella
- MMR
- Poliovirus
- Hepatitis
- HIB
- Other Pediatric
Adult Vaccines:
- Influenza
- Cervical Cancer
- Hepatitis
- Pneumococcal
- Travel; DT; Misc.
The global market for vaccines experienced strong growth in many categories through 2013, declines in others, and this is expected to continue through the forecast period. Growth is being fueled by new product introductions and rising usage in all regions. Kalorama provides a global perspective in this report, including estimates of vaccine sales (pediatric and adult segments) in the following regions:
- U.S.
- Rest of North Amer.
- South America
- Europe
- Japan
- India
- China
- Rest of World
Despite ongoing improvements in pediatric vaccination, it is estimated that at least two million children die each year from diseases that could have been prevented by already existing vaccines. This problem is most significant in low income countries, with the health disparity between rich and poor countries resulting in average life spans of about 77 and 52 years, respectively. In addition to this high death toll, millions more suffer disability and illness because they have not been immunized.
Adult immunization is an important, but frequently overlooked, part of patient care. Though vaccination programs typically focus on children, adults in industrialized countries are more likely to die as a result of vaccine-preventable diseases than are children. For example, vaccination can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly. Pharmacoeconomic studies have demonstrated the value of influenza and pneumococcal vaccines; however, immunization rates for these diseases continue to be low in the elderly populations.
Key issues in the global vaccine market today include product safety, refusal to immunize, supply shortages, the use of vaccines to prevent pandemics and address bioterrorism, and innovations in vaccine delivery systems. The following issues are discussed in this report.
- Vaccine Safety
- Refusal to Immunize
- Obesity
- Post-Licensure Surveillance
- The Future of Vaccine Safety
- Vaccine Shortages
- Preventing Pandemics
- Project Bioshield Act
- National Bio and Agro-Defense Facility
- DNA Vaccination
- Mucosal Delivery
- Intranasal Delivery
- Vaccine Patches
- Vaccine Chips and Microneedles
- Innovations in Vaccine Production
- Nanoparticle Systems
- Cloning
This report includes profiles of the key players in vaccines, including:
- AlphaVax, Inc.
- Bavarian Nordic A/S
- Baxter Healthcare
- Bharat Biotech
- Crucell /Johnson & Johnson
- Emergent biosolutions
- GlaxoSmithKline
- Medimmune
- Merck & Co. Inc
- Novartis
- Sanofi Pasteur
- Pfizer
